The Access to Medicine Foundation has published a report which finds ‘clear evidence of progress’ by pharmaceutical companies over the past 10 years in improving access to medicines.
The report analyses the world’s 20 largest drug companies and found that there had been a big improvement in the research and development pipeline for 47 ‘high-burden and priority’ diseases and conditions.
Making the announcement, Exective Director of the Access to Medicine Foundation, Jayasree K. Iyer said:
“Compared with ten years ago, pharmaceutical companies are taking seriously the problems people face in low- and middle-income countries when accessing healthcare. The situation is still fragile – a retreat by one company, or a drop in healthcare investments, will jeopardise the progress made so far.”
The report also looks at the driving factors behind this change. According to the Access to Medicine Foundation, these include:
“The report shows that, in specific areas, more companies are taking action to improve global health than ten years ago. It also identifies an effective recipe for bringing pharmaceutical companies on board. This recipe consists of setting clear priorities endorsed by the international community of experts in global health. It also requires publicly funded mechanisms for reducing the risks companies face when investing in global health, or for shaping markets with little prospect of profitability.”
Read more on the issue of access to medicines in MAP’s Access to Orphan Medicines: A Case for Change.